Inflammatory Biomarkers in Post-infarction Heart Failure and Cardiac Remodeling

Frunza, Olga; Frangogiannis, Nikolaos G.

doi:10.1016/b978-0-12-800039-7.00007-4

Cited by 1 publication

(1 citation statement)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, high mobility group box protein 1 (HMGB1) is highly expressed in phagocytic microglia [ 164 ], which may reflect AD progression [ 165 , 166 ] as well as ischemic stroke, TBI, and MS severity [ 167 , 168 , 169 , 170 ]. Galectin-3 drives microglial activation [ 171 , 172 , 173 , 174 ] and is associated with a worse AD [ 175 , 176 ], TBI, and stroke [ 173 , 177 , 178 ]. Fractalkine/CX3 chemokine ligand 1 (CX3CL1) is higher in the plasma of patients with lower stroke severity [ 179 ].…”

Section: Clinical Assessment Of Microglial Activation and Cns-infiltr...mentioning

confidence: 99%

Cross-Talk and Subset Control of Microglia and Associated Myeloid Cells in Neurological Disorders

Mills

Ladner

Soliman

et al. 2022

Cells

View full text Add to dashboard Cite

Neurological disorders are highly prevalent and often lead to chronic debilitating disease. Neuroinflammation is a major driver across the spectrum of disorders, and microglia are key mediators of this response, gaining wide acceptance as a druggable cell target. Moreover, clinical providers have limited ability to objectively quantify patient-specific changes in microglia status, which can be a predictor of illness and recovery. This necessitates the development of diagnostic biomarkers and imaging techniques to monitor microglia-mediated neuroinflammation in coordination with neurological outcomes. New insights into the polarization status of microglia have shed light on the regulation of disease progression and helped identify a modifiable target for therapeutics. Thus, the detection and monitoring of microglia activation through the inclusion of diagnostic biomarkers and imaging techniques will provide clinical tools to aid our understanding of the neurologic sequelae and improve long-term clinical care for patients. Recent achievements demonstrated by pre-clinical studies, using novel depletion and cell-targeted approaches as well as single-cell RNAseq, underscore the mechanistic players that coordinate microglial activation status and offer a future avenue for therapeutic intervention.

show abstract